Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0XXQVC
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
AA-A225
|
|||||
| Synonyms |
Antiangiogenesis program (Actinium Pharmaceuticals); AA A225; Actinium-225 conjugated to daratumumab
Click to Show/Hide
|
|||||
| Organization |
Actinium Pharmaceuticals, Inc.
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 1 Indication(s)
|
|||||
| Antibody Name |
Daratumumab
|
Antibody Info | ||||
| Antigen Name |
ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (CD38)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Linker Name |
Undisclosed
|
|||||
